Bisphosphonates antagonise bone growth factors' effects on human breast cancer cells survival.
Bone tissue constitutes a fertile 'soil' for metastatic tumours, notably breast cancer. High concentrations of growth factors in bone matrix favour cancer cell proliferation and survival, and a vicious cycle settles between bone matrix, osteoclasts and cancer cells. Classically, bisphosphonates interrupt this vicious cycle by inhibiting osteoclast-mediated bone resorption. We and others recently reported that bisphosphonates can also induce human breast cancer cell death in vitro, which could contribute to their beneficial clinical effects. We hypothesised that bisphosphonates could inhibit the favourable effects of 'bone-derived' growth factors, and indeed found that bisphosphonates reduced or abolished the stimulatory effects of growth factors (IGFs, FGF-2) on MCF-7 and T47D cell proliferation and inhibited their protective effects on apoptotic cell death in vitro under serum-free conditions. This could happen through an interaction with growth factors' intracellular phosphorylation transduction pathways, such as ERK1/2-MAPK. In conclusion, we report that bisphosphonates antagonised the stimulatory effects of growth factors on human breast cancer cell survival and reduced their protective effects against apoptotic cell death. Bisphosphonates and growth factors thus appear to be concurrent compounds for tumour cell growth and survival in bone tissue. This could represent a new mechanism of action of bisphosphonates in their protective effects against breast cancer-induced osteolysis.
Fromigue
O
O
Laboratory of Endocrinology, Bone Diseases and Breast Cancer Research, Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles. Rue Heger-Bordet, 11000 Brussels, Belgium.
Kheddoumi
N
N
Body
J-J
JJ
D017209:Apoptosis; D001859:Bone Neoplasms / Q000556:secondary*; D001842:Bone and Bones / Q000502:physiology; D001943:Breast Neoplasms / Q000473:pathology*; D002470:Cell Survival; D004164:Diphosphonates / Q000494:pharmacology*; D005260:Female; D006133:Growth Substances / Q000494:pharmacology*; D006801:Humans; D010014:Osteolysis / Q000517:prevention & control; D010766:Phosphorylation; D014407:Tumor Cells, Cultured
D004164:Diphosphonates; D006133:Growth Substances